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Abstract
Background:  The performance of the Charlson and Elixhauser comorbidity measures in
predicting patient outcomes have been well validated with ICD-9 data but not with ICD-10 data,
especially in disease specific patient cohorts. The objective of this study was to assess the
performance of these two comorbidity measures in the prediction of in-hospital and 1 year
mortality among patients with congestive heart failure (CHF), diabetes, chronic renal failure (CRF),
stroke and patients undergoing coronary artery bypass grafting (CABG).
Methods: A Canadian provincial hospital discharge administrative database was used to define 17
Charlson comorbidities and 30 Elixhauser comorbidities. C-statistic values were calculated to
evaluate the performance of two measures. One year mortality information was obtained from the
provincial Vital Statistics Department.
Results: The absolute difference between ICD-9 and ICD-10 data in C-statistics ranged from 0 to
0.04 across five cohorts for the Charlson and Elixhauser comorbidity measures predicting in-
hospital or 1 year mortality. In the models predicting in-hospital mortality using ICD-10 data, the
C-statistics ranged from 0.62 (for stroke) – 0.82 (for diabetes) for Charlson measure and 0.62 (for
stroke) to 0.83 (for CABG) for Elixhauser measure.
Conclusion: The change in coding algorithms did not influence the performance of either the
Charlson or Elixhauser comorbidity measures in the prediction of outcome. Both comorbidity
measures were still valid prognostic indicators in the ICD-10 data and had a similar performance
in predicting short and long term mortality in the ICD-9 and ICD-10 data.
Background
Administrative hospital discharge abstract data are widely
used in studies of healthcare outcomes. For valid and
meaningful comparisons of providers, risk adjustment is
essential since risk factors of outcomes are unevenly dis-
tributed across providers and variation in baseline status
could make a major contribution to differences in patient
outcomes. Risk adjustment is a complex construct that
involves patient's socio-demographic factors (e.g. age,
gender, and race), acute clinical stability, severity of pri-
mary disease, functional status, and burden of comorbid-
ity [1]. As major determinants of patient outcomes,
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comorbidities or coexisting conditions have been studied
extensively for decades. Many methods have been devel-
oped to measure and control comorbidities. The Charlson
[2] and Elixhauser comorbidity measures [3] are two com-
monly used instruments for risk adjustment analyses.
Charlson et al.[2] studied numerous clinical conditions by
reviewing inpatient hospital charts and assessing their rel-
evance in the prediction of mortality. A weighted score
was assigned to each of 17 comorbidities and the Charl-
son index was created as an indicator of disease burden.
Elixhauser et al.[3] used sets of individual ICD-9-CM diag-
nosis codes to identify categories of comorbidities. They
measured 30 individual comorbidities that are associated
with mortality. The performance of the Charlson and Elix-
hauser measures in predicting poor outcomes has been
assessed on various large populations [4-11]. These stud-
ies consistently demonstrated that they were valid prog-
nostic measures of outcomes.
The World Health Organization adopted the first version
of the International Classification of Disease (ICD) in
1900 to internationally monitor and compare mortality
statistics and causes of death. Since then, the classification
has been revised periodically to accommodate new
knowledge of disease and health. The sixth revision, pub-
lished in 1949, was more radical than the previous five
revisions because this edition made it possible to record
information from patient charts to compile morbidity sta-
tistics. Subsequent revisions were made in 1958 (7th ed.),
in 1968 (8th ed.) and in 1979 (9th ed.). The latest version
ICD-10, was introduced in 1992 to replace the ICD-9
[12]. The United States modified ICD-9 by specifying
many categories and extending coding rubrics to describe
the clinical picture in more detail. These modifications
resulted in the publication of ICD-9-CM in 1979 for cod-
ing diagnoses in patient charts [13].
Many countries such as Canada, Australia, New Zealand,
Japan, China and European countries have already imple-
mented the ICD-10. When compared to the ICD-9, the
ICD-10 has a more comprehensive scope, effective struc-
ture, presentation and guidelines and allows for enhance-
ments to accommodate newly discovered diseases [14].
The codes in ICD-10 are alphanumeric whereas codes in
ICD-9 are numeric. Each code in ICD-10 starts with a let-
ter (i.e. A to Z), followed by two numeric digits, a decimal
point, and a digit (e.g. I21.4 for acute subendocardial
myocardial infarction). In contrast, codes in ICD-9-CM
begin with three digit numbers (i.e. 001 to 999), that are
followed by a decimal and up to two digits (e.g. 410.7 for
subendocardial infarction).
Since implementation of the ICD-10, researchers have
been evaluating the performance of the Charlson and
Elixhauser comorbidity measures using ICD-10 data.
Quan et al.[7] developed ICD-10 coding algorithms to
define Charlson and Elixhauser comorbidities and
assessed the performance of the resulting algorithms in
predicting in-hospital mortality. Sundarajan et al.[15]
used Australian ICD-10 administrative data to evaluate
the Charlson comorbidity measure in predicting in-hospi-
tal mortality. In both studies, the adaptation of the Charl-
son comorbidity measure for use with ICD-10 data
yielded similar prevalence and prognosis information to a
Charlson comorbidity measure based on ICD-9-CM.
These two studies assessed the performance of Charlson
or Elixhauser measures in risk-adjustment in adult hospi-
tal admissions. However, these studies did not test the
performance of the Charlson and Elixhauser comorbidity
measures in predicting short and long term mortality in
disease specific patient cohorts using ICD-10 administra-
tive data. The present study addresses the above gap by
using a large Canadian provincial hospital discharge
administrative database containing ICD-9 and ICD-10
codes. Our study assesses the performance of Charlson
and Elixhauser comorbidity measures in predicting in-
hospital and one year mortality in five cohorts, including
patients with congestive heart failure (CHF), diabetes,
chronic renal failure (CRF), stroke and patients undergo-
ing coronary artery bypass grafting (CABG).
Methods
Data source
This study employed hospital discharge abstract data
(DAD) from the province of British Columbia, Canada
between April 01, 1997 and March 31, 2004. The DAD
contains demographic, administrative and clinical data
for all hospital discharges in the province. British Colum-
bia adopted the ICD-10 coding system in 2001. Prior to
2001, each discharge record contained up to 16 ICD-9
diagnosis codes and 10 procedure codes of the Canadian
Classification of Diagnostic, Therapeutic and Surgical Pro-
cedures (CCP). Since 2001, each record contained up to
25 ICD-10 diagnosis codes and 20 procedure codes of the
Canadian Classification of Health Interventions (CCI).
For each diagnosis code in ICD-9 and ICD-10 data, a one
digit 'diagnosis-type' code was assigned to specify the tim-
ing of diagnosis. Those occurring after hospital admission
were assigned as complications. In order to be compara-
ble with ICD-9 data, we truncated the ICD-10 data with
the first 16 diagnosis codes and 10 CCI procedure codes.
Study population
Five study populations were defined during 1997 and
2004 fiscal years (March 31 to April 1), four years prior to
(1997 to 2000) and four years post (2001 to 2004) ICD-
10 implementation. For each study cohort, we excluded
non-British Columbia residents and those younger thanBMC Health Services Research 2008, 8:12 http://www.biomedcentral.com/1472-6963/8/12
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20 years of age. For stroke, diabetes, CHF, and CRF study
cohorts, all admissions with diagnostic codes of each of
these chronic conditions at the most responsible diagno-
sis coding field were selected (see Table 1 for ICD-9 and
ICD-10 diagnostic codes). For patients with more than
one admission, only the first admission was selected for
each patient as the index admission. Conditions coded as
a hospital complication were excluded through searching
the 15 secondary diagnosis and diagnosis type coding
fields. We further excluded those with length of hospital
stay one day or less and discharged alive. The CABG study
cohort was defined by including all hospitalizations with
the 851 CCP code for ICD-9 and 1IJ76 CCI code for ICD-
10 data. For those with multiple admissions, the latest
admission was assigned to each patient as the index
admission.
Defining comorbidities and mortality
Quan et al.[7] developed the enhanced ICD-9-CM and
ICD-10 coding algorithms to define Charlson and Elix-
hauser comorbidities. We slightly revised the enhanced
ICD-9-CM coding algorithms by keeping the first 4
numerical digits for diagnosis codes with a 5th digit.
Then, the slightly revised ICD-9-CM and original ICD-10
coding algorithms were employed respectively to define
the 17 Charlson and 30 Elixhauser comorbidities in ICD-
9 and ICD-10 data.
The outcome of interest was in-hospital and 1 year mor-
tality. In-hospital mortality was defined using death flag
in the DAD. To determine 1 year mortality after admis-
sion, inpatient records were linked with the British
Columbia Vital Statistics registry using deterministic
record linkage method. The common identifiers between
two databases are personal health number, surname, sex,
date of birth. The personal health number is unique
numerical identifier but is not available in all death
records. Therefore, we determined deaths based on
matching on all of these identifiers. The possibility of
linking one inpatient record to two deaths is very rare. We
used the same matching strategy to match inpatients and
death records in another Canadian province and found
that the correct-linkage rate is about 98% [16]. The regis-
try captures all deaths that occurred in the province. The
mortality used in this study was all cause mortality.
Statistical analysis
We first calculated the frequencies of Charlson and Elix-
hauser comorbidities in ICD-9 and ICD-10 data in each
study cohort. Four logistic regression models were fit for
ICD-9 data. Model 1 included in-hospital mortality as the
dependent variable and age, sex, and Charlson comorbid-
ities as the independent variable. Model 2 included in-
hospital mortality as the dependent variable and age, sex,
and Elixhauser comorbidities as the independent varia-
bles. Model 3 was fit using 1 year mortality after admis-
sion as the dependant variable and age, sex, and Charlson
comorbidities as the independent variable. Model 4
included 1 year mortality after admission as the depend-
ent variable and age, sex, and Elixhauser comorbidities as
the independent variables. Then, we fit these four logistic
regression models for ICD-10 data. In these eight models,
we defined age and individual Charlson and Elixhauser
comorbidities as binary variables. Age was categorized as
< 65 and = 65 years old. Another option for adding Charl-
son comorbidities in the models is to weight each comor-
bidity and add the weighted index as an independent
variable. A recent study [17] illustrated that the use of the
individual comorbidities in model building performs bet-
ter than the use of the weighted index for predicting mor-
tality.
C-statistic values were calculated to assess performance of
logistic regression models in discriminating mortality.
The C-statistic is the area under the receiver operating
characteristic (ROC) curve, measuring the ability of the
predictive model to discriminate among those who do
and do not die. A value of C = 0.5 indicates random pre-
diction and C = 1 indicates perfect prediction [1]. We per-
formed a bootstrapping procedure with 800 replications
to determine approximate 95% confidence interval for C-
statistic. Data analyses were conducted using SAS version
8.1 [18].
Table 1: Coding definition for four study cohorts
ICD-10 ICD-9
Congestive hear 
failure
I43, I50, I099, I110, I130, I132, I255, I420, I425–I429, P290 4254, 4255, 4257, 4258, 4259, 428
Diabetes E100, E101, E106, E108–E111, E116, E118–E121, E126, E128–E131, E136, E138–E141, 
E146, E148, E149, E102–E105, E107, E112–E115, E117, E122-E125, E127, E132–E135, 
E137, E142–E145, E147
250
Chronic renal 
failure
N18 585
Stroke G45, H341, I60, I61, I63, I64 3623, 430, 431, 433–436BMC Health Services Research 2008, 8:12 http://www.biomedcentral.com/1472-6963/8/12
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Results
Frequencies of mortality and comorbidities in each study
cohort are presented in Table 2. The mortality rates were
quite similar for the chronic conditions of stroke, diabe-
tes, CHF, and the procedure of CABG for the years
spanned by the ICD-9 and ICD-10 databases. The mortal-
ity rate was however increased in the patients of CRF.
There were also no obvious differences between two data-
bases in the proportions of senior and female in each
study cohort. When comparing the five cohorts, the dia-
betics were relatively younger than other four study
cohorts. The portion of males in the CABG cohort was
higher than in other cohorts, and accounted for almost
80% of the cohort. The frequencies of Charlson and Elix-
hauser comorbidities were generally similar for ICD-9 and
ICD-10 data in each cohort. However renal failure was
more frequent in ICD-9 than ICD-10 across the five study
cohorts. Diabetes with complication was more prevalent
in the ICD-10 data than in the ICD-9 data.
Tables 3 and 4 present the C-statistics of Charlson and
Elixhauser comorbidity measures in predicting mortality
in the ICD-9 and ICD-10 data. The C-statistics were simi-
lar between ICD-9 and ICD-10 datasets for each study
cohort using either the Charlson or Elixhauser comorbid-
ity measure to predict in-hospital or 1 year mortality. The
absolute difference in C-statistics across cohorts ranged
from 0 to 0.04. Using Charlson comorbidities to predict
in-hospital mortality, the C-statistics for five cohorts
ranged from 0.62 (for stroke) to 0.82 (for diabetes) in the
ICD-10 data. Using Elixhauser measure to predict in-hos-
pital mortality, the C-statistics ranged from 0.62 (for
stroke) to 0.83 (for CABG) in the ICD-10 data. The C-sta-
tistics increased when these two measures predicted 1 year
mortality in stroke cohort but declined for remaining 4
cohorts studied.
Discussion
We compared the performance of the Charlson and the
Elixhauser comorbidity measures in predicting short and
long term mortality among patients with CHF, diabetes,
CRF, stroke, and CABG between ICD-9 and ICD-10 Cana-
dian hospital discharge abstract databases. We found that
most comorbidities studied had similar frequencies across
ICD-9 and ICD-10 databases although variations were
observed for some comorbidities. The performance of the
Charlson and Elixhauser comorbidity measures in dis-
criminating mortality was similar in ICD-9 data as well as
ICD-10 data across five study cohorts.
In the patients with CHF and stroke, the C-statistic values
for the predicting in-hospital or 1 year mortality were
notably low with values of 0.63 and 0.66 for CHF and
0.62 and 0.67 for stroke, respectively. The low values
might reflect the fact that some powerful clinical predic-
tors of poor outcomes were not included in these meas-
ures due to a lack of information in the administrative
databases, such as ejection fraction and severity of stroke.
We also demonstrated that both of the comorbidity meas-
ures performed better in predicting 1-year mortality than
in-hospital mortality in the patients with stroke. This find-
ing provides evidence that severity and type of stroke
(such as hemorrhage or ischemic attach) should be con-
sidered to improve risk adjustment performance. In con-
trast to stroke, the performance of the Charlson and
Elixhauser measures in discriminating mortality among
patients with CHF, diabetes and undergoing CABG
declined with length of prediction.
The quality of data used for risk adjustment will affect the
reliability and validity of the model. The introduction of
new coding schemata, such as the ICD-10, presents signif-
icant issues regarding coding accuracy and completeness
of clinical information. The magnitude of changes
between coding schemes from ICD-9 to ICD-10 may
induce coding errors unless efforts are taken to prepare
coders for the changes through education and practice ses-
sions and post implementation monitoring and quality
improvement steps to reduce any notable errors or misin-
terpretations in coding practices. Our findings showed
that most comorbidities had similar frequencies across
ICD-9 and ICD-10 databases and the performance of two
co-morbidity measures in discriminating mortality was
similar between ICD-9 data and ICD-10 datasets across
five study cohorts. The results suggest that the implemen-
tation of ICD-9 and ICD-10 might have similar validity.
These results may reflect efforts to improve the quality of
coding pre and post implementation of ICD-10 by the
British Columbia Ministry of Health.
ICD-10 was implemented in Canadian hospitals in differ-
ent years for each province. British Columbia introduced
ICD-10 in 2001 fiscal year. Before the implementation,
detailed coding standards for the new classification sys-
tem were developed, and health records professionals
were intensively trained. Following the collection of the
first year's data, data quality concerns in the ICD-10 data
were collected and reviewed. The review led to various ini-
tiatives to further improve training and data quality,
including clarification of coding requirements for certain
conditions, and re-abstracting records for validity assess-
ment. The first post implementation pan-Canadian re-
abstraction study was taken in 2003/04 [19]. At the same
time, a Data Quality Framework was introduced by CIHI
and new edit checks were implemented to address incor-
rect application of coding standards and other data qual-
ity issues. An ongoing schedule for national re-abstraction
studies has been established.BMC Health Services Research 2008, 8:12 http://www.biomedcentral.com/1472-6963/8/12
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Table 2: Frequency of independent and dependent variables (%) in ICD-9 (1997–2000) and ICD-10 (2001–2004) data
Congestive Heart Failure Diabetes Chronic renal failure Stroke CABG
ICD-10
(% of 25969)
ICD-9
(% of 30008)
ICD-10
(% of 11918)
ICD-9
(% of 11411)
ICD-10
(% of 1770)
ICD-9
(% of 2076)
ICD-10
(% of 22947)
ICD-9
(% of 28984)
ICD-10
(% of 10214)
ICD-9
(% of 9578)
In-hospital 
Mortality
12.4 11.6 4.2 3.7 16.8 13.2 17.0 15.4 2.9 3.3
One year Mortality 40.1 39.7 19.0 17.7 42.0 34.1 29.2 26.1 5.1 5.5
Male 50.2 51.5 55.9 54.4 55.0 56.7 49.6 50.9 79.7 78.6
Senior 85.9 86.8 45.3 44.8 65.0 58.0 77.9 78.5 60.4 59.9
Charlson 
comorbidities
Myocardial 
infarction
9.6 15.1 3.6 4.9 3.6 5.7 3.4 5.2 19.3 36.1
Congestive 
heart failure
- - 8.1 8.2 18.9 15.1 4.7 4.3 19.6 16.0
Peripheral 
vascular disease
2.1 4.9 11.2 10.2 3.6 3.3 1.7 3.8 5.2 7.4
Cerebrovascula
r disease
2.2 3.6 2.5 3.8 2.2 3.0 - - 5.4 6.8
Dementia 3.8 2.9 3.4 2.4 3.2 1.0 5.6 3.9 0.5 0.1
Chronic 
pulmonary 
disease
16.2 19.6 3.5 5.0 5.5 6.1 3.8 5.2 4.7 8.0
Rheumatic 
disease
0.8 1.4 0.7 0.8 2.0 2.5 0.6 0.9 0.3 0.6
Peptic ulcer 
disease
0.4 0.3 0.4 0.3 0.3 0.6 0.3 0.3 0.8 1.2
Mild liver 
disease
0.8 1.0 1.2 1.6 1.7 1.5 0.3 0.4 0.2 0.5
Diabetes 
without chronic 
complication
24.0 23.1 - - 16.3 18.3 17.1 15.5 25.6 22.8
Diabetes with 
chronic 
complication
4.2 1.8 - - 6.4 2.7 1.5 0.8 5.3 2.8
Hemiplegia or 
paraplegia
0.4 0.6 0.6 1.1 0.5 0.6 14.0 16.1 0.7 0.9
Renal disease 14.2 10.2 17.2 14.9 - - 2.6 1.6 5.9 3.1
Any malignancy 2.4 2.7 2.0 1.7 4.7 3.1 2.1 2.0 0.9 1.0
Moderate or 
severe liver 
disease
0.4 0.3 0.3 0.3 0.7 0.4 0.1 0.1 0.1 0.1
Metastatic solid 
tumor
0.7 0.7 0.8 0.5 1.6 0.5 0.8 0.8 0.1 0.0
AIDS/HIV 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1
Elixhauser 
comorbidities
Congestive 
heart failure
- - 8.1 8.2 18.9 15.1 4.7 4.3 19.6 16.0
Cardiac 
arrhythmia
28.2 30.0 4.8 6.0 8.5 7.4 13.5 13.8 31.7 36.3
Valvular disease 10.5 12.4 0.8 1.3 2.8 2.6 1.5 2.1 20.3 17.4
Pulmonary 
circulation 
disorders
1.9 2.0 0.3 0.2 0.5 0.5 0.4 0.3 1.3 1.9
Peripheral 
vascular 
disorders
2.1 4.9 11.2 10.2 3.6 3.3 1.7 3.8 5.2 7.4
Hypertension 19.4 20.2 20.0 22.2 23.8 22.3 31.4 32.4 33.6 41.6
Hypertension, 
uncomplicated
15.9 18.1 14.4 17.1 14.5 19.7 30.2 31.7 30.7 39.9
Hypertension, 
complicated
3.5 2.1 5.6 5.1 9.3 2.6 1.2 0.7 2.9 1.7
Paralysis 0.4 0.6 0.6 1.1 0.5 0.6 14.0 16.1 0.7 0.9
Other 
neurological 
disorders
1.1 1.5 2.2 2.3 2.2 2.6 8.2 8.1 1.0 1.4
Chronic 
pulmonary 
disease
16.2 19.6 3.5 5.0 5.5 6.1 3.8 5.2 4.7 8.0
Diabetes, 
uncomplicated
23.3 22.9 - - 15.7 18.1 16.8 15.3 25.4 22.7
Diabetes, 
complicated
4.8 2.0 - - 7.0 2.8 1.7 1.0 5.5 2.9
Hypothyroidism 1.6 2.4 1.6 2.0 1.1 1.5 1.3 1.4 0.8 1.3
Renal failure 14.2 8.7 17.2 10.4 - - 2.6 1.1 5.9 1.6BMC Health Services Research 2008, 8:12 http://www.biomedcentral.com/1472-6963/8/12
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Limitations of our study have to be acknowledged before
making conclusions. We assessed comorbidity measures
in two different periods, 1997–2000 for ICD-9 and
2001–2004 for ICD-10. We could not exclude contribu-
tion of temporal change in disease prevalence and data
quality to model performances. Both Charlson and Elix-
hauser measures consist of chronic diseases and their
prevalence may not vary much in such a short period as
our findings of similar frequencies for many comorbidi-
ties across two databases. The second limitation is that our
findings might not be applicable to other diseases or pro-
cedures. We selected inpatients with four conditions and
one procedure. We found the performance of Charlson
and Elixhauser comorbidity measures varied across five
study cohorts. Therefore one should be cautious when
generalizing our findings beyond these conditions and
procedure. The third limitation is that we defined comor-
bidities using index admission. Employing previous
admission records to define comorbidities will increase
prevalence of these conditions, resulting in a better risk
adjustment [20,21]. However, our study conclusions may
not be altered due to the length of the lookback because
the same method of ascertaining comorbidities was
applied to both databases.
Conclusion
In conclusion, the change in disease coding system from
ICD-9 to ICD-10 did not impact the performance of
Charlson and Elixhauser comorbidity measures in the pre-
diction of mortality. Both measures were acceptable prog-
nostic predictors for diabetes, CRF, and CABG in outcome
research and performed similarly.
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Table 4: Performance of Charlson and Elixhauser comorbidities in predicting one year mortality (C-statistic, 95% confidence interval)
Congestive heart failure Diabetes Chronic renal failure Stroke CABG
ICD-10 ICD-9 ICD-10 ICD-9 ICD-10 ICD-9 ICD-10 ICD-9 ICD-10 ICD-9
Charlson 0.63 0.64 0.77 0.76 0.76 0.76 0.65 0.66 0.77 0.73
comorbidities (0.63–0.63) (0.63–0.64) (0.76–0.77) (0.76–0.77) (0.75–0.78) (0.75–0.78) (0.65–0.65) (0.66–0.66) (0.76–0.79) (0.72–0.77)
Elixhauser 0.64 0.64 0.77 0.76 0.78 0.77 0.65 0.67 0.78 0.79
comorbidities (0.64–0.65) (0.64–0.65) (0.77–0.78) (0.76–0.77) (0.77–0.79) (0.76–0.79) (0.65–0.66) (0.67–0.67) (0.75–0.81) (0.76–0.80)